乌司奴单抗在银屑病及银屑病关节炎中的长期心血管安全性:基于瑞典国家登记的前瞻性观察性上市后安全性研究
该研究基于瑞典国家登记数据,纳入2009至2021年起始治疗的成人银屑病或银屑病关节炎患者,比较乌司奴单抗与阿达木单抗、依那西普或司库奇尤单抗的主要不良心血管事件风险。共纳入15,502例患者(852例使用乌司奴单抗),观察到147例MACE。调整后风险比无显著差异,提示乌司奴单抗在真实临床实践中未显示不同的心血管安全性特征。
要点
- 乌司奴单抗与阿达木单抗、依那西普或司库奇尤单抗相比,主要不良心血管事件风险无显著差异。
- 研究基于瑞典国家登记的真实世界数据,随访超过10年。
- 结果支持乌司奴单抗在银屑病及银屑病关节炎患者中的长期心血管安全性。
核心结论
- 在瑞典银屑病及银屑病关节炎患者中,乌司奴单抗与阿达木单抗、依那西普或司库奇尤单抗相比,主要不良心血管事件风险无显著差异。
研究设计与样本
- 基于瑞典国家登记的新使用者、活性对照观察性队列研究,纳入2009至2021年起始治疗的成人银屑病或银屑病关节炎患者,共15,502例,其中852例使用乌司奴单抗。
主要发现
- 随访期间共观察到147例主要不良心血管事件。
- 乌司奴单抗对比阿达木单抗的调整后风险比为1.07(95%CI 0.49-2.33)。
- 乌司奴单抗对比依那西普的调整后风险比为1.08(95%CI 0.48-2.42)。
- 乌司奴单抗对比司库奇尤单抗的调整后风险比为1.19(95%CI 0.46-3.10)。
临床怎么用
- 在临床实践中,乌司奴单抗的长期心血管安全性与其他常用生物制剂相当,可为治疗选择提供参考。
局限性
- 观察性研究,药物分配非随机化,且缺乏疾病严重程度数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on the comparative cardiovascular (CV) safety of ustekinumab in psoriasis (PsO) and psoriatic arthritis (PsA) remains limited. OBJECTIVE: To assess the risk of major adverse cardiovascular events (MACE) among PsO and PsA patients treated with ustekinumab compared to those treated with adalimumab, etanercept, or secukinumab in routine clinical practice. METHODS: This new-user, active-comparator, observational cohort study used patient-level data from Swedish national registers, including adult PsO/PsA patients initiating treatment with ustekinumab or a comparator between 2009 and 2021, with patients assigned to mutually exclusive cohorts. The primary outcome was incident MACE, defined as myocardial infarction, ischemic stroke, or CV-related death. Adjusted hazard ratios were estimated using cause-specific Cox regression with stabilized inverse probability of treatment weighting by propensity scores. RESULTS: A total of 15,502 patients were included (852 ustekinumab-treated), with 147 MACE observed during follow-up. Adjusted hazard ratios (95% CI) comparing ustekinumab to adalimumab, etanercept, and secukinumab were 1.07 (0.49-2.33), 1.08 (0.48-2.42), and 1.19 (0.46-3.10), respectively. LIMITATIONS: Observational study, drug allocation not randomized, and lack of disease severity data. CONCLUSION: This nationwide study of Swedish PsO/PsA patients spanning >10 years found no evidence of different CV safety profiles of ustekinumab versus adalimumab, etanercept, or secukinumab in real-world clinical practice.
引用
- Banefelt J, Skröder H, Azzabi A, et al. Long-term cardiovascular safety of ustekinumab in psoriasis and psoriatic arthritis: Results from an observational postauthorization safety study based on Swedish national registers. J Am Acad Dermatol. 2025. PMID: 40089022. doi:10.1016/j.jaad.2025.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。